Abstract: As cholangiographic features of IgG4-related sclerosing cholangitis (IgG4-SC) resemble those of cholangiocarcinoma, it is highly confusing between the 2 conditions on the basis of cholangiographic findings. This study presents a case of extensive metastatic cholangiocarcinoma with IgG4-SC misdiagnosed as isolated IgG4-SC, and reviews recent studies of the 2 diseases.
INTRODUCTION
C holangiocarcinoma, first reported by Durand-Fardel in 1840, 1 accounts for the second most common primary hepatic tumor worldwide. 2 It is a difficult-to-diagnose condition that usually presents late, and is associated with a high mortality. Characteristic features of the entity include abdominal pain, biliary strictures, and jaundice. 3 Although unspecific, serological studies, such as serum bilirubin, liver enzymes (alkaline phosphatase [ALP] , g-glutamyl transpeptidase, and the transaminases), tumor markers (carbohydrate antigen [CA19-9] and carcinoembryonic antigen [CEA] ), are useful as a diagnostic guide.
IgG4-related sclerosing cholangitis (IgG4-SC) is a new emerging disease which was identified by Hamano et al at 2001 . 4 Given that fact that clinical cholangiographic features of IgG4-SC resemble those of cholangiocarcinoma, 5, 6 it is highly confusing between the 2 conditions in cholangiographic findings. Herein, we describe a case of extensive metastatic cholangiocarcinoma with IgG4-SC that was wrongly diagnosed as isolated IgG4-SC solely on the basis of serum and tissue IgG4 levels, and conduct an overview of the published literature on this issue.
CASE REPORT
A 56-year-old man with no family history of malignant tumors or liver diseases presented with recurrent mild abdominal pain and distention for 3 months. Duration of pain may last from hours to days, and the pain caused a loss of appetite. He lost 3 kg in body weight in half a month before admission. Physical examination showed mild tenderness in the upper abdomen, without rebound tenderness, guarding, mass, or hepatomegaly. Serum tests revealed that slightly elevated IgG4 (216 mg/dL; normal range, 3-200 mg/dL) and CA19-9 (48.06 U/mL; normal < 37 U/mL). Total bilirubin, conjugated bilirubin, and liver function parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), ALP, and albumin, remained normal (Table 1) by the time of admission.
Ultrasonography of the abdomen demonstrated chronic cholecystitis and heterogeneous echogenicity in the liver. Next, magnetic resonance cholangiopancreatography (MRCP) investigation showed a solid nodular lesion at 3.7 cm in size with unclear boundary in segment VI of the liver (Fig. 1A, left) . This mass-forming lesion caused obstructive intrahepatic bile duct (Fig. 1A, right) . Transversal sections with T1-hypointense (Fig. 1B, left) and T2-hyperintense (Fig. 1B, right) showed a moderate enhancement of the common bile duct. Dilation and irregularity of intrahepatic bile duct were also obvious. Moreover, no enlarged retroperitoneal lymph node was found.
Based on the imaging results, a liver core needle biopsy under ultrasound guide was performed with the aim to exclude malignancy. Histopathological examination revealed conspicuous inflammatory cell infiltration consisting largely of plasmacytes, macrophages, and lymphocytes on a background of fibrous interstices with fibrosis and fibroblast proliferation. Plasmatic infiltrates were particularly apparent, with a portion showing atypia such as polynuclear cells, and represented reactive growth. Proliferative storiform fibrosis was found, which is characterized by a cartwheel sign with spindle cells radiating from a center ( Fig. 2A) . Immunohistochemistry revealed that the proportion of IgG4/IgG-positive plasma cells was 59.3% (32/54; Fig. 2B and C). These histologic findings were consistent with the consensus statement on the pathology of IgG4-SC, 7 and therefore, IgG4-SC was highly considered as a diagnosis.
In the view of his slight symptoms, glucocorticoid was not given at first. Considering that liver-occupying lesion and chronic cholecystitis may further lead to abnormal liver function, treatment was initially started with liver protective drug (silymarin, containing about 60% polyphenole silibinin, has a protective effect on hepatocytes and anti-inflammatory effect on bile ducts and gallbladder). [8] [9] [10] However, 3 months after his first MRCP, he had more severe abdominal pain and further elevated serum CA19-9, and was admitted to our hospital again. At this time, the results of MRCP were similar to that of the first one. But enlargement of supraclavicular lymph nodes was suspected by physical examination, which was confirmed by ultrasonography examination (largest 0.7 cm). Due to suspected spread of malignancy accompanied with intraabdominal inflammation and adhesion, laparoscopy was not considered to avoid unnecessary pain and expense. Thus, an exploratory laparotomy in the liver was performed in the surgery department of this hospital. During the surgery, a tumor at 5 cm in size in the segment VI of the liver was found to invade into the whole layer of the duodenum and transverse colon wall, as well as the serous membrane of the gallbladder wall. Diffuse miliary nodules were observed on abdominal wall, parietal peritoneum, omentum, and diaphragm (Table 2 ). These nodules under microscopy were featured with typical metastatic adenocarcinoma, while heterocysts were observed in the removed gallbladder that confirmed as poorly differentiated adenocarcinoma (Fig. 2D) . Significantly, immunohistochemical staining of IgG4 was also positive for tumor specimens (Fig. 2E) . The patient then received palliative treatment and died from multiorgan failure secondary to systemic metastasis 3 months later, and the final diagnosis was extensive metastatic cholangiocarcinoma with IgG4-SC.
Institutional approval of what was given by Institutional Ethics Committee of Zhongshan Hospital of Fudan University (Shanghai, China), and informed consent was given by the patient.
DISCUSSION
IgG4-related disease (IgG4-RD) is a fibroinflammatory, multiorgan condition of unknown etiology with commonly shared features that include elevated serum IgG4 concentrations, tumefactive lesions, storiform fibrosis, as well as dense lymphocyte and IgG4-positive plasmacyte infiltrates. 11 Clinically, symptoms (including pruritus, weight loss, abdominal distention or pain, and obstructive jaundice), are all nonspecific, and could also be found in both IgG4-SC and cholangiocarcinoma. 12 It is not easy to distinguish IgG4-SC from primary sclerosing cholangitis (PSC), pancreatic cancer, and cholangiocarcinoma on the basis of cholangiographic findings alone. [13] [14] [15] Radiologic features of IgG4-SC, such as thickening bile duct wall, mimic that of cholangiocarcinoma, and other inflammatory or immunemediated disorders, such as PSC. [16] [17] [18] For laboratory tests of IgG4-SC, abnormal liver functions, such as elevated bilirubin (65%), ALP (84%), ALT (62%), and AST (32%), could be seen. 12 However, these abnormal values varied widely among IgG4-SC patients, thus it is hard to find a proper cut-off value to differentiate IgG4-SC from cholangiocarcinoma.
In spite of large similarities in clinical, imaging, and biochemical characteristics, notably, there are still significant differences between IgG4-SC and cholangiocarcinoma (Table 3) . Two gastrointestinal symptoms (including steatorrhea and abdominal pain), rarely reported in patients with IgG4-SC, 12 were presented in this case. The pathophysiology is unclear but seems to reflect a direct gastrointestinal effect in this part of patients and in our case. However, jaundice was absent in our case, which was presented in most IgG4-SC patients. It is possible that IgG4-SC accompanied with autoimmune pancreatitis increases the chance of obstructive jaundice. Further, tumor was found in segment VI of the liver, while the intrahepatic bile ducts were partly dilated in our case. This may partly explain normal total bilirubin and conjugated bilirubin.
Although molecular mechanisms for elevated serum IgG4 and IgG4-positive plasma cells remains largely unknown, serum IgG4 level could be considered as a noninvasive and proven test for the diagnosis of IgG4-SC. 19 In our study, serum IgG4 level of this patient was slightly rising (216 mg/dL); while Straub et al 20 reported that serum IgG4 level (84 mg/dL) is within the normal range in the co-occurrence of cholangiocarcinoma with IgG4-SC. By comparison, a cross-sectional study of 53 IgG4-SC patients found that mean serum IgG4 level is 516 AE 98 mg/dL (mean AE SE), and the level over 280 mg/dL accounts for up to 50%.
12 It seems that serum IgG4 level in cholangiocarcinoma is not as high as that in IgG4-SC. Ohara et al 21 conducted a cohort study to establish a cut-off value for
IgG4 level with the expectation of distinguishing IgG4-SC from other non-IgG4-related hepatopancreatobiliary diseases. The cut-off level of serum IgG4 was set at 135 mg/dL to differentiate all the 344 IgG4-SC patients from pancreatic cancer, PSC, and cholangiocarcinoma controls. However, it is noteworthy that the specificity of the value is low for distinguishing IgG4-SC from cholangiocarcinoma, especially those with cholangiocarcinoma and PSC. Moreover, Oseini et al 22 suggested that serological IgG4 concentrations above 4 times the upper limit of the normal range is more specific for IgG4-SC.
Serum CA19-9 has long been used as a prognostic indicator for various cancer patients (including pancreatitis, colon cancer, and bile duct diseases) during follow-up evaluations after surgery, radiotherapy, and/or chemotherapy. [23] [24] [25] It was also elevated both in IgG4-SC and in cholangiocarcinoma (Table 1) . 26 Therefore, efforts were made to set up a proper cut-off value to differentiate cholangiocarcinoma from other diseases. However, according to a previous study conducted by Li et al, 12 average CA19-9 level was 91 AE 30 U/mL in cholangiocarcinoma, while over 37 U/mL accounting for 48% and over 100 U/mL accounting for 18%. Further, a study reported by Levy et al 27 found that the sensitivity and specificity are 78.6% and 98.5%, respectively, at the cut-off value of 129 U/mL for cholangiocarcinoma, although the positive predictive value is only 56.6%. In this study, serum CA19-9 level for this 56-year-old male was 148.06 U/mL at admission. A continuous elevation was noted after he was diagnosed with IgG4-SC; however, a rapid reduction was then observed 1 day after surgery (Fig. 3) . Additionally, AFP and CEA levels remained normal before surgery. We infer that sustained elevation of serum CA19-9 may imply the occurrence of tumor in hepatobiliary system of IgG4-RD, and subsequent decline could be due to gallbladder resection. Since the existence of the difficulty to define a proper cut-off value and of the poor diagnostic power of serum CA19-9, the dynamic monitoring of serum CA19-9 may be, in our opinion, used to follow-up patients on immunosuppressive therapy.
Integrated positron emission tomography and computed tomography (PET/CT) with 18 18 F-FDG uptake by the hilar lymph node is significantly more frequent in autoimmune pancreatitis (a major constituent of IgG4-RD) than in pancreatic cancer. Based on the experience in the management of this case, we feel that 18 F-FDG PET/CT is likely to be one potential key modality in the assessment of the overall condition of patients with IgG-SC. However, 18 F-FDG PET/CT does not appear to have a well-established role in the diagnosis of patients with IgG4-SC in this case. Future prospective studies are required to define the cost-effectiveness and clinical impact in the management of patients with IgG4-SC.
It is well known that inflammation contributes to the pathogenesis of cholangiocarcinoma. 33 A variety of cytokines and growth factors involved in proliferation, apoptosis, senescence, and cell-cycle regulation are required for the development of cholangiocarcinoma genesis. It is well-known that PSC, another autoimmune biliary disease, has been regarded as one of the most common predisposing condition for cholangiocarcinoma with 0.5% to 1.5% of PSC patients developing into cholangiocarcinoma per year. 34 As a result, the chronic inflammation microenvironment of IgG4-SC may also be involved in the pathogenesis of cholangiocarcinoma. In this case, immunohistochemical staining of interleukin-4 (IL-4, a Th2 type cytokine), IL-17, interferon-g (INF-g, a Th1 type cytokine), and Foxp3 (the marker of Tregs) was performed. IL-4 þ cells scattered in the germinal centers and the Disse space without preference (Fig. 4A) , while INF-g þ cells mainly gathered around the bile ducts (Fig. 4B) . Generally, IgG4-RD is Th-2 type cytokines dominant, 11 in other words, the amount of IL-4 þ cells surpasses that of INF-g þ cells. Despite no expression of INF-g þ cells was reported in previous study of isolated IgG4-SC, a moderate expression of INF-g þ cells was, however, detected in bile ducts of this case, which may be due to the co-occurrence of cholangiocarcinoma and IgG4-SC. Further, markedly elevation of Foxp3 þ lymphocytes, a specific cell surface marker of Treg, 5 was scattered in the germinal centers of lymph follicle (Fig. 4C) . It is commonly known that the function of Tregs is impaired in classic autoimmune diseases. 35 FIGURE 3. Dynamic changes of serum tumor marker: serum carbohydrate antigen 19-9 (CA19-9), alpha-fetoprotein (AFP), and carcinoembryonic antigen (CEA). Serum CA19-9 level showed a sustained elevation before surgery and then a rapid drop after surgery. Serum AFP and CEA remained normal between the interval of the first and the second admission. In the present study, the activation of Tregs was considered possibly to be a secondary response that prohibits the overreaction of Th2-dominated autoimmunity of IgG4-SC. 36 Also, the expression of intratumor IL-17 þ cells (a novel IL-17-producing CD4 þ T helper cell subset) has not been reported in IgG4-SC previously, but was detected in the germinal centers and the Disse space without preference in this patient (Fig. 4D) . 37 However, the exact immunological mechanism responsible for the changed cytokine profile is not clear, and future studies may warrant defining their functional roles in the pathogenesis of cholangiocarcinoma and/or IgG4-SC.
Only a few studies have reported the cooccurrence of IgG-RD and malignancies within the same organ, such as the cooccurrence of IgG4-SC and cholangiocarcinoma. 20, 38, 39 At present, a great deal of effort has been focused in differentiating IgG4-SC from cholangiocarcinoma in order to avoid arbitrary surgical resections. However, misdiagnosis of cholangiocarcinoma as IgG4-SC, on the other hand, resulted in delaying in optimal surgical time, and consequently, the use of steroid drugs in these patients will lead to tumor dissemination. Therefore, what would be the proper management algorithm in this scenario? Once IgG4-SC is diagnosed and the immunosuppressive drug is given, we recommend follow-up of serum IgG4 and CA19-9, as well as the imaging examination such as ultrasound, CT or MRI scanning. Cholangiocarcinoma should be reconsidered if there is no sign of reduction in tumor size, decreased serum IgG4 levels or continuous elevation of serum CA19-9 level after the treatment. At that time, repeated core needle biopsy should be considered. Laparoscopy is also an option to consider when a contraindication does not exist. Further, although not the first choice, 18 F-FDG PET/CT could be served as an approach to follow-up the therapeutic response of IgG4-SC under the consent of patients.
Curative surgery is the best way to obtain good survival for resectable cholangiocarcinoma. However, chemotherapy was the optimal therapy for this extensive metastatic patient. Combination chemotherapy with gemcitabine and cisplatin has become the practical therapies for cholangiocarcinoma. 40 Two randomized clinical trials 41 reported that combination use of the 2 agents had a better survival rate compared with patients using these 2 drugs separately. However, responses of these chemotherapies are limited and the 5-year survival remains low. 42 Targeted therapy using Lapatinib, a dual epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2) kinase inhibitor, was significantly effective in inhibiting of the growth of human cholangiocarcinoma cell lines. 43 A phase I study is still underway, investigating the role of Dovitinib, small molecule fibroblast growth factor receptor (FGFR) inhibitor, in combination with gemcitabine and capecitabine in patients with biliary cancers. 44 Additionally, a phase I trial of everolimus, a mammalian target of rapamycin (mTOR) inhibitor, in combination with gemcitabine and cisplatin, points to a promising future for cholangiocarcinoma patients who are refractory to conventional therapies. 45 
CONCLUSION
In conclusion, we surmised that IgG4-SC and cholangiocarcinoma are not 2 separate entities; investigating whether they share common molecular abnormalities may lead to a better understanding of their relationship. At present, it is hard to make it clear whether these 2 diseases have a causal or just a coincidental association. 5, 13 Thus, although low incidence of the cooccurrence of IgG4-SC and cholangiocarcinoma exits, we highly recommend repeated core needle biopsy or even laparoscopy/laparotomy before immunosuppressive drugs are given in addition to the laboratory test of serum and tissue IgG4 levels. Follow-up of the serum CA19-9 and imaging evidences should continue once immunosuppressive therapy starts. 18 F-FDG PET/CT should also take into consideration when imaging examinations (such as CT or MRI scanning) fail to help.
